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Abstract
A current challenge in breast cancer (BC) patients is how to reduce the side effects
of cancer and cancer treatments and prevent a decrease in quality of life (QoL).
Neurotoxic side effects, especially from chemotherapy, are present in up to 75% of
women with BC, which implies a large impact on QoL. There is a special interest in
the preventive possibilities of therapeutic exercise (TE) for these neurological se-
quelae, and the benefits of TE could be improved when it is combined with vagal
activation techniques (VATs). This superiority randomized controlled trial aims to
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examine the feasibility and efficacy of an 8‐week multimodal intervention (ATENTO)
based on moderate‐vigorous intensity and individualized TE (aerobic and strength
exercises) and VAT (myofascial and breathing exercises), on neurotoxicity prevention in
women with BC before starting adjuvant chemotherapy (ATENTO‐B) versus throughout
adjuvant chemotherapy (ATENTO‐T). A sample of 56 women newly diagnosed with BC,
as calculated with a power of 85%, will be randomly allocated into these two groups. This
study could provide an impetus for the introduction of early multimodal intervention
methods to prevent neurotoxicity and consequently avoid the QoL deterioration that BC
patients presently suffer throughout their treatments.
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1 | BACKGROUND
Quality of life (QoL) is a major concern in cancer care from the
moment of diagnosis (Fernández de Larrea‐Baz et al., 2020). Cancer‐
and cancer treatment‐related side effects, namely neurotoxicity,
have a negative impact on overall QoL. Neurotoxicity, which affects
both the central and peripheral nervous system in 45%–75% of
women with breast cancer (BC; Janelsins et al., 2014; Winters‐Stone
et al., 2017), is considered a sign of poor prognosis and survival
(Goldstein et al., 2016) and could limit treatment completion (Stone
& DeAngelis, 2016). Some patients show remission of these com-
plications after treatments, but in up to 45%, they are present for
several years (Huehnchen et al., 2020). Central and peripheral neu-
rotoxicity in BC comprises a wide range of signs and symptoms, such
as cognitive impairment, anxiety and depression, delirium, headache,
cerebellar dysfunction, extrapyramidal disorders, tingling, numbness,
and weakness (Stone & DeAngelis, 2016). Although its etiology is still
unclear, several mechanisms of neurotoxicity have been proposed:
chemotherapy‐related mitotic inhibition (affecting neuronal function
and survival; Hershman et al., 2014); the ability of some che-
motherapeutic agents to cross the brain–blood barrier and directly
damage central nervous system (Tanimukai et al., 2013); peripheral
inflammation derived from tumor factors or psychological distress;
and the increase in oxidative stress and mitochondrial dysfunction
that activate the apoptotic pathway (Gordon‐Williams & Farquhar‐
Smith, 2020). Moreover, neurotoxic symptoms co‐occur with certain
comorbidities such as psychological distress, fatigue, sleep disorders,
and pain that exacerbates one another and reduces overall QoL
(Chae et al., 2018; Hong et al., 2014). As a result, BC patients could
develop a potent morbidity from the neurotoxicity that, in turn,
worsens their prognosis. Therefore, they require a powerful, com-
prehensive intervention.
Therapeutic exercise (TE) has positive effects for cancer prevention
(Jones, 2015), relief of symptoms (Cormie et al., 2017), and improvement
of survival (Morishita et al., 2020). For example, the effects of exercise on
the nervous system have been widely studied, namely inducing neuro-
genesis as well as influencing the cellular proliferation of the dendrites,
which help to prevent neurodegenerative diseases. In addition, preclinical
studies suggest that TE could prevent neurotoxic symptoms, such as
cognitive impairment, by improving hippocampal plasticity and mi-
tochondrial function (Park et al., 2018). Likewise, TE seems to enhance
the effectiveness of chemotherapy and radiotherapy (Schadler
et al., 2016), improving medication perfusion and patient immune cell
infiltration through modification of the vascular network surrounding the
tumor (Aschcraft et al., 2019). In particular, there is strong support for
the efficacy of TE during and after cancer treatment in women with BC in
terms of QoL improvement, central and peripheral neurotoxicity in terms
of cognitive impairment, anxiety and depression symptoms, and numb-
ness and tingling (Campbell et al., 2020; Mishra et al., 2012; Streckmann
et al., 2014). Therefore, is an urgent need for TE to be adapted to the
condition of the individual patient since excessive doses are counter-
productive (Jones, 2015). Two strategies have been proposed to objec-
tively regulate TE: (i) measurement of heart rate variability, an index of
autonomic nervous system function, that reflects the interplay of the
sympathetic and parasympathetic nervous system (Coumbe &
Groarke, 2018); (ii) m‐health devices to monitor the recovery of patients
in real‐time after sessions (Medina Quero et al., 2017), which has an
important role in prevention and rehabilitation programs (Debon
et al., 2019).
In parallel, the use of vagal activation techniques (VATs; such as
myofascial and breathing exercises) may reinforce the benefits of TE.
Some authors highlighted the importance of stress reduction to avoid
inflammatory and hormonal responses resulting in neurotoxicity in on-
cological patients (Lacourt & Heijnen, 2017). As stress reduces para-
sympathetic activity, interventions targeted at improving vagal function
are recommended for reducing inflammatory status (Woody et al., 2017).
Emergent research proposes to explore multimodal interventions
(i.e., TE plus VAT) before BC treatment to reduce short‐ and long‐term
sequelae. The combination of both TE and VAT could be a powerful
option for these BC patients, but its efficacy has not yet been studied.
Considering the positive dose–response relationship between exercise
intensity and beneficial outcomes, high‐intensity exercise has been sug-
gested (Campbell et al., 2020). Prehabilitation may physically prepare
these patients for cancer treatment and may benefit their long‐term
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health and QoL (Giles & Cummins, 2019). While the theoretical bases of
prehabilitation are well established, it is unknown whether the devel-
opment of these multimodal programs is more effective before the be-
ginning of adjuvant chemotherapy or throughout this treatment in terms
of neurotoxicity prevention. Therefore, we designed the protocol “Ad-
justing the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to
Anticancer Treatment (ATENTO),” to examine which phase would be
more effective for preventing QoL deterioration through prevention of
cancer treatment‐related neurotoxicity.
1.1 | Objectives of the present study
The main objective of this study will be to analyze the effect of a
multimodal program on overall QoL through prevention of neuro-
toxicity in women with BC when the program is performed at two
different time‐points: before (ATENTO‐B) or throughout (ATENTO‐T)
adjuvant chemotherapy. The specific objectives are as follows:
‐ To assess and compare the effects of ATENTO‐B versus ATENTO‐
T on QoL, clinical variables, and physical variables for BC at the
end of adjuvant chemotherapy, at 6‐month follow‐up, and at 12‐
month follow‐up.
‐ To examine how changes in clinical and physical variables related
to neurotoxicity affect changes in QoL outcomes in women
with BC.
We hypothesize that women who perform the ATENTO‐B mul-
timodal program will have better QoL and lower neurotoxicity than
those women who perform ATENTO‐T.
2 | METHODS
The methodology for this study will follow the directives from the SPIRIT
2013 Statement (standard protocol items: Recommendations for inter-
ventional trials) and from the Consolidated Standards of Reporting
Trials statement (Figure 1). This trial has been approved by the Institu-
tion's Committee of Biomedical Research Ethics and follows the princi-
ples of the Helsinki Declaration (2013 version). The study will be carried
out in accordance with the data protection law (3/2018).
2.1 | Design
The ATENTO study is a single‐blind, two‐armed, superiority rando-
mized controlled trial.
2.2 | Participants, recruitment, and setting
Eligible patients will be recruited from the institution's breast unit by
three surgeons and the nurse in charge at the time of diagnosis, following
the criteria described below. After receiving general information about
the study in the hospital, patients will be contacted by a researcher to
make an appointment and perform baseline assessment (t0) 2–4 days
after BC diagnosis. All participants will be informed verbally and in
writing, and written informed consent will be obtained before performing
assessments.
Women will be included in the study if they accomplish the following
inclusion criteria: (a) age between 18 and 70 years, (b) having a BC
diagnosis (Stage I–III), and (c) on the waiting list for adjuvant che-
motherapy with risk of central and peripheral neurotoxicity (che-
motherapy based on anthracyclines or taxanes regimen). Exclusion
criteria are (a) having a previous history of cancer or any cancer treat-
ment, (b) pregnancy, (c) participating in another intervention that could
influence on the outcomes (e.g., TE, body‐mind therapy) or (c) having a
neurodegenerative disease that affects the central or peripheral nervous
system and could influence the results.
2.3 | Data collection
Assessments will be conducted at baseline between 2 and 4 days after
BC diagnosis (t0), 1 or 2 weeks after adjuvant chemotherapy for BC (t1),
at the 6‐month follow‐up (t2), and at the 12‐month follow‐up (t3). The
endpoint measures are detailed below. All of these assessments will be
carried out by a single researcher with more than 3 years of experience
in the facility. We will divide the assessment protocol into 2 separate
days to reduce participant burden. All assessments will take place at the
same time of day. Table 1 provides the assessment schedule and data
collection time points.
2.4 | Measures
2.4.1 | Quality of life
QoL will be measured using the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐
C30) version 3.0 (Aronson et al., 1993). This tool is composed of five
functional scales, three symptom scales, a global health status/QoL scale,
and six single‐items. Responses range from 0 to 100, where higher scores
represent better QoL (Fayers et al., 2001). The EORTC QLQ‐C30 is a
reliable measure with a Cronbach's alpha for global QoL subscale of 0.89
(Aronson et al., 1993).
2.4.2 | Central neurotoxicity
The Trail Making Test (TMT) will be used to assess mental flexibility,
speed of processing, and executive function. The TMT consists of two
parts: in Part A the subject draws lines sequentially connecting
numbers from 1 to 25 as fast as possible; and in Part B the subject
draws lines to connect the numbers numerically and the letters al-
phabetically as fast as possible, alternating numbers and letters in
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consecutive order. The time spent on both tasks is noted. The total
completion time for Part B minus the total completion time for Part
A is used as an indicator of cognitive flexibility. A smaller B −A dif-
ference (s) indicates better cognitive flexibility (Tombaugh, 2004).
Memory and cognitive processing speed will be measured using
two of the four score indexes from the Wechsler Adult Intelligence
Scale (Wechsler, 2008): the Working Memory Index (WMI) (composed
of the digit span and arithmetic subtests) and the processing speed
index (PSI) (composed of the symbol search and coding subtests). The
WMI and PSI have demonstrated high reliability (Cronbach's α: 0.94
and 0.90, respectively; Watkins, 2017).
2.4.3 | Peripheral neurotoxicity
The EORTC QLQ‐Chemotherapy‐induced peripheral neuropathy (QLQ‐
CIPN20) will be used to assess neuropathic symptoms (Postma
et al., 2005). This tool is composed of 20 items scored from 0 to 4
classified into three subscales: sensory, motor, and autonomic
symptoms. Higher scores indicate a greater presence of symptoms.
The CIPN20 has Cronbach's α coefficients ranging from 0.78 to 0.88
(Kieffer et al., 2017).
Semmes‐Weinstein monofilaments (SWMs) will be used to detect
peripheral sensory neuropathy (Bell‐Krotoski et al., 1995). They will
be used on 14 points on the hands and feet (right and left).
Monofilaments will be applied in order of stiffness, three times per
point. The first monofilament (the thinnest) the patient feels at each
point of application will be noted. SWMs are a valid tool for iden-
tifying subclinical peripheral neuropathy in cancer (da Silva Simão
et al., 2014).
2.4.4 | Other general variables
The Hospital Anxiety and Depression Scale (HADS) will be used to as-
sess such symptoms (Zigmond & Snalth, 1983). It consists of 14 items
scored from 0 to 3 and grouped into two subscales: anxiety and
depression. The HADS has a Cronbach's α of 0.90 for the full scale,
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The Piper Fatigue Scale‐Revised (PFS‐R) will be used to assess
cancer‐related fatigue (Piper et al., 1998). The PFS‐R consists of
22 self‐report items that are scored from 0 to 10 points and
grouped into four subscales (behavioral, emotional, sensorial, and
cognitive subscales) and a global index, in which higher scores
indicate the greater impact of fatigue. This scale has been vali-
dated in Spanish BC patients obtaining satisfactory reliability and
validity values (Cronbach's α: 0.87–0.94; Cantarero‐Villanueva
et al., 2014).
The short form of the Brief Pain Inventory (BPI) will be used to
assess pain severity and the interference of pain with daily activities
(Poquet & Lin, 2016). The BPI consists of four items for severity and
seven for interference. The scores range from 0 (no pain/no inter-
ference) to 10 (worst imaginable pain). The BPI has a Cronbach's α
ranging from 0.87 to 0.89 (Badia et al., 2003).
Pressure pain thresholds will be used to explore the quadriceps, del-
toid, trapezius, and cervical muscles bilaterally using an algometer. Each
point will be stimulated three times, and the mean value for each one
point will be considered. The examiner will instruct patients to warn
when the pressure sensation changes into pain. Algometry has been
demonstrated to be reliable (intraclass coefficient correlation [ICC] =
0.91; Chesterton et al., 2007).
The Pittsburgh Sleep Quality Index (PSQI) will be used to evaluate
sleep quality (Buysse et al., 1989). It consists of 19 self‐reported items
and five questions reported by a roommate not considered for the
analysis. Items are grouped into seven subjective dimensions: quality,
latency, duration, efficiency, disturbances, medication use, and day-
time dysfunction. Each item is scored on a 0–3 scale, with a total score
ranging from 0 to 21 where higher scores indicate worse sleep quality.
The PSQI is a reliable tool in cancer (Fontes et al., 2017).





















Quality of life X X X X
Central
neurotoxicity
X X X X
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neurotoxicity
X X X X
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X X X X
Fatigue X X X X
Pain X X X X
Quality of sleep X X X X
Cardiorespiratory
fitness
X X X X
Static body balance X X X X
Physical activity
level
X X X X
Body composition X X X X
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2.4.5 | Physical variables
A cardiopulmonary exercise test will be performed with aMedisoft, 870A
treadmill and Jaeger MasterScreen® CPX gas analyser to assess peak VO2
according to the protocol of the University of Northern Colorado Cancer
Rehabilitation Institute. The protocol includes twenty‐one 1‐min exercise
stages. This protocol is a valid method for establishing peak VO2 (Kee
Shackelford et al., 2017).
We will use the Flamingo test to assess whole‐body balance.
The test consists of balancing on their preferred foot with the
free leg flexed at the knee and the foot of this leg held against the
buttocks. The that the subject is able to hold this position for up
to 30 s is noted. The average of both legs will be used in the
analysis. Lower scores indicate better whole‐body balance (Nà-
cher Roig et al., 1998). This test has shown good reproducibility
with an ICC of 0.82 (Vancampfort et al., 2019).
2.4.6 | Physical activity level
One of the short forms of the International Physical Activity Questionnaire
(IPAQ) will be used to measure the physical activity or inactivity level
(Craig et al., 2003). It includes seven open‐ended questions relating to
physical activity in the last week. The IPAQ is a reliable tool in cancer
patients (Ruiz‐Casado et al., 2016).
2.4.7 | Anthropometrics
We will use an InBody 720 impedanciometer that estimates lean
body mass, fat mass, abdominal adipose tissue, and body max
index (kg/m2) and provides reliable results (Thomas et al., 2001).
2.4.8 | Additional parameters
Sociodemographic and clinical data will be collected with a self‐
report questionnaire. Stage of cancer, history of cancer and re-
lationship, treatments received, and treatment reductions or in-
terruptions will be recorded via a mobile app (ATOPE+)
developed by our research team (https://www.safecreative.org/
work/2010285737407‐atope). The ATOPE+ app will also be used
to record data about TE session's modifications and adverse
effects.
2.5 | Randomization and blinding
After baseline assessment (t0), randomization will be performed by
an independent researcher using a computer‐generated number
(EPIDAT 4.2 Xunta de Galicia). The program distributes each number
to one of two lists, one for the ATENTO‐B group and the other for
the ATENTO‐T group. The allocation of each participant will be
known by the researcher who will carry out the intervention. Data
analysis will be performed by a blinded researcher (M. A. M).
2.6 | Intervention
All participants of this study will perform the ATENTO program but
in different timing: before (ATENTO‐B) or throughout (ATENTO‐T)
adjuvant chemotherapy (see Figure 2).
ATENTO is a face‐to‐face, multimodal 8 weeks program.
ATENTO is based on TE combining supervised individual aerobic and
strength exercises, following VAT at the participating institution, and
a home‐based physical activity promotion using a steps per day
strategy (Tudor‐Locke & Bassett, 2004) monitored with FITBIT ac-
tivity bracelets (Inspire, HR, Fitbit). The intervention will be con-
ducted and supervised by a specialist in TE who will ensure the
correct execution and adaptation of all exercises for each patient.
Implementation processes and adaptations will be recorded by the
intervention checklist to guarantee fidelity. For the first 2 weeks, the
main objective will be to improve general physical health and to
correctly execute each exercise. After this, more specific physical
exercises will be used. A nonlinear prescription (with daily load and
frequency of sessions per week) will be determined with a mobile
app (ATOPE+; Moreno‐Gutierrez et al., 2021), according to FIIT
(frequency, intensity, time, and type) parameters (Campbell
et al., 2019); see Table 2 that shows the ATENTO program in detail.
The intensity of the aerobic and strength exercises will be controlled
according to heart rate (Nilsen et al., 2018) and perceived exertion
(Garnacho‐Castano et al., 2018). Each session will have three parts:
F IGURE 2 ATENTO program timings. Created with Biorender.com[Color figure can be viewed at wileyonlinelibrary.com]
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an overall warm‐up of 8–10min (light intensity aerobic, joint mobi-
lity, and stretching exercises), the main part of 60min with cardio-
vascular (10–30min) and strength (30–50min) exercises, and a final
part of 20min with VAT exercises aimed at promoting physical and
mental recovery. Elliptical trainer, elastic bands, dumbbells, and mats
will be required for the implementation of the program.
2.7 | Statistical analyses and sample size
calculation
We will use the Statistical Package for the Social Science (IBM©
SPSS© Statistic version 25 Corp.) considering significant results at
p ≤ 0.05. Analysis of data will be based on intention‐to‐treat and
imputation methods will be used for missing data.
Characteristics of the participants at baseline will be described
for the entire sample, and study groups (ATENTO‐B and ATENTO‐T).
Continuous data will be summarized as mean and standard deviation
(m ± SD), while categorical variables will be summarized as number
and percentage (n, %). The normality of the variables will be checked
with the Kolmogorov–Smirnov test and visual reinforcement. A
baseline comparison will be made to test homogeneity between two
groups using the Student's t test or Mann–Whitney U as appropriate.
A generalized linear mixed model will be used to test the effect
of the ATENTO program on QoL, central and peripheral neurotoxi-
city, and the remaining health outcomes, analyzing the time X group
interaction for between‐ and within‐group changes. All models will
be adjusted for statistically significant baseline differences. The
magnitude of change over time and differences by the group will be
calculated using Cohen's d effect size values.
The sample size was calculated using the EORTC QLQ‐C30
version 3.0 (Aronson et al., 1993) and calculations from the
previous study to detect a mean difference in the global QoL
subscale between the ATENTO‐B and ATENTO‐T groups of 14.6
(69.5 ± 18.0 vs. 54.9 ± 19.6; Steindorf et al., 2019). Assuming an α
error of 0.05, a power of 85% and an effect size of 0.79 (based on
the results of the reference study), we need a sample of 24
participants for each group (G*Power v. 3.1). Assuming a possible
15% dropout rate, based on a previous similar study (Mijwel
et al., 2018) in which 14 participants dropped out after rando-
mization and 10% dropped out during the intervention, we will
recruit 28 participants per group (total n = 56).
3 | DISCUSSION
This study will target avoiding QoL reduction through the prevention
of neurotoxicity. To this end, we will study the efficacy of ATENTO, a
multimodal program based on TE and VAT, performed at two dif-
ferent time points: before and throughout adjuvant chemotherapy in
women with newly diagnosed BC.
Early evidence suggests the implementation of prehabilitation
programs in oncological patients is more powerful than rehabilitation
interventions (Treanor et al., 2018). Exercise‐based interventions
have been demonstrated to be optimal in primary and secondary
prevention in cancer patients (Bade et al., 2015). Improvements in
QoL have also been observed with intervention programs before
surgical and systemic treatments for cancer (Treanor et al., 2018). In
addition to improving posttreatment outcomes, prehabilitation may
be one way to maximize treatment effectiveness, recovery, and
survival (Giles & Cummins, 2019). In addition, multimodal interven-
tions before medical treatments appear to provide better treatment
experiences than unimodal interventions (Santa Mina et al., 2017).
Our study aims to determine whether an early multimodal program
based on TE and VAT can prevent neurotoxicity and QoL reduction
derived from medical treatment in women newly diagnosed with BC.
There are some limitations in this study. The short and variable
period of time between cancer diagnosis and surgery, as well as the
TABLE 2 The ATENTO program components in detail
ATENTO progam
Frequency: >2 days/week depending of recovery following ATOPE+ results
Components
General phase Specific phase
Time (min) or volume Intensity Time (min) or volume Intensity




HRR (Luan et al., 2019)
10–20′ Moderate–high
40%–85%
HRR (Luan et al., 2019)












VAT Myofascial exercises 10–15′ – 10–15′ –
Breathing techniques 8–10′ – 10–15′ –
Abbreviations: HRR, heart rate reserve; RM, repetition maximum; VAT, vagal activation techniques.
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psychological impact of diagnosis, could make adherence and com-
pletion of the program difficult for the ATENTO‐B group. However,
just 3–4 weeks of moderate‐vigorous prehabilitation involving phy-
sical exercise has benefits for tumors in BC (Ligibel et al., 2019) and a
review has shown that prehabilitation is feasible with good levels of
adherence (Treanor et al., 2018). Also, we will control psychological
status during the intervention program, and we will consider a
minimum of 75% of adherence.
If ATENTO‐B obtains better feasibility and efficacy results
than ATENTO‐T, similar programs should be piloted for the time
interval between diagnosis and surgery. In addition, that window
may be an excellent opportunity to provide care, prepare BC
patients for medical treatment and survivorship, improve post-
treatment outcomes, and reduce the use of health services. In
contrast, if ATENTO‐T results in better outcomes, it may be ne-
cessary to consolidate the protocols for the application of this
type of multimodal program based on tailored TE and VAT in BC
patients. In summary, our results may help to improve the pro-
tocols of multimodal programs that prevent and address
treatment‐related side effects such as neurotoxicity and to im-
prove QoL in women newly diagnosed with BC.
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